同源康医药-B(02410)：联交所就实施H股全流通授出上市批准

Core Viewpoint - The company, ZhiYuanKang Pharmaceutical-B (02410), has applied to the Hong Kong Stock Exchange for approval to list and trade 4.608 million H-shares converted from non-listed shares held by a shareholder, with approval granted on February 11, 2026 [1] Group 1 - The company has submitted an application to the listing committee of the Hong Kong Stock Exchange [1] - The application involves the conversion of 4.608 million non-listed shares into H-shares [1] - The listing approval was granted by the Hong Kong Stock Exchange on February 11, 2026 [1]